Jae Hyuk Yoo

Jae Hyuk Yoo

Auto-generated profile, based on publicly available information

Jae Hyuk Yoo

Department of Ophthalmology & Visual Sciences, Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2019 in Pigment Cell & Melanoma Research
Verified
Journal Article
Open access
PDF file
JRJackson R. Richards
Jackson R. Richards
JYJae Hyuk Yoo
Jae Hyuk Yoo
DSDonghan Shin
Donghan Shin
SOShannon J. Odelberg
Shannon J. Odelberg
Uveal melanoma is the most common primary malignancy of the eye, and a number of discoveries in the last decade have led to a more thorough molecular characterization of this cancer. However, the prognosis remains dismal for patients with metastases, and there is an urgent need to identify treatments that are effective for this stage of disease. Animal models are important tools for preclinical studies of uveal melanoma. A variety of models exist, and they have specific advantages, disadvantages, and applications. In this review article, these differences are explored in detail, and ideas for new models that might overcome current challenges are proposed.

9 December 2008 in FEBS Letters
Verified
Journal Article
Open access
HKHo Soo Kim
Ho Soo Kim
MJMi Soon Jung
Mi Soon Jung
KLKyunghee Lee
Kyunghee Lee
KKKyung Eun Kim
Kyung Eun Kim
JYJae Hyuk Yoo
Jae Hyuk Yoo
WCWoo Sik Chung
Woo Sik Chung
MINT‐6800978:AtCaM2 (uniprotkb:P25069) physically interacts (MI:0218) with CBRLK1 (uniprotkb:Q9ZT06) by cytoplasmic complementation assay (MI:0228)

27 July 2023 in Oncogene
Verified
Journal Article
Closed access
PDF file
JRJackson R. Richards
Jackson R. Richards
DSDonghan Shin
Donghan Shin
RPRob Pryor
Rob Pryor
LSLise K. Sorensen
Lise K. Sorensen
ZSZhonglou Sun
Zhonglou Sun
JYJae Hyuk Yoo
Jae Hyuk Yoo

8 September 2023 in Oncogene
Verified
Journal Article
Open access
PDF file
JRJackson R. Richards
Jackson R. Richards
DSDonghan Shin
Donghan Shin
RPRob Pryor
Rob Pryor
LSLise K. Sorensen
Lise K. Sorensen
ZSZhonglou Sun
Zhonglou Sun
JYJae Hyuk Yoo
Jae Hyuk Yoo

4 November 2022 in Research Square
Verified
Preprint
Open access
PDF file
JYJae Hyuk Yoo
Jae Hyuk Yoo
JRJackson Richards
Jackson Richards
DSDonghan Shin
Donghan Shin
RPRob Pryor
Rob Pryor
LSLise Sorensen
Lise Sorensen
SOShannon Odelberg
Shannon Odelberg
Preventing or effectively treating metastatic uveal melanoma (UM) is critical because it occurs in about half of patients and confers a very poor prognosis. There is emerging evidence that hepatocyte growth factor (HGF) and insulin-like growth factor 1 (IGF-1) promote metastasis and contribute to the striking metastatic hepatotropism observed in UM metastasis. However, the molecular mechanisms by which HGF and IGF-1 promote UM liver metastasis have not been elucidated. ASAP1, which acts as an effector for the small GTPase ARF6, is highly expressed in the subset of uveal melanomas most likely to metastasize. Here, we found that HGF and IGF-1 hyperactivate ARF6, leading to its interaction with ASAP1, which then acts as an effector to induce nuclear localization and transcriptional activity of NFAT1. Inhibition of any component of this pathway impairs cellular invasiveness. Additionally, knocking down ASAP1 or inhibiting NFAT signaling reduces metastasis in a xenograft mouse model of UM. The discovery of this signaling pathway represents not only an advancement in our understanding of the biology of uveal melanoma metastasis but also identifies a novel pathway that could be targeted to treat or prevent metastatic uveal melanoma.